Regenexx Corporate

What Regenexx Corporate does

Regenexx Corporate is a privately held healthcare company, headquartered in Des Moines, Iowa, that sells non-surgical interventional orthopedic procedures as a covered benefit under self-funded employer health plans. The company markets to self-funded employers (100+ employees), benefits brokers, and third-party administrators (TPAs), positioning its bone marrow concentrate (BMC) and platelet-based procedures — delivered via precisely guided, needle-based, image-guided injections — as a lower-cost alternative to orthopedic surgery for joint and soft tissue conditions.

Its core technology stack is anchored by proprietary devices and treatment methods protected by 24 issued patents and supported by what the company describes as the world's largest human mesenchymal stem cell re-implantation registry. Product portfolio includes the Regenexx Corporate Program (the employer-facing benefit), a Live Patient Outcomes Database (transparency/credibility tool), a Savings Calculator, a Benefits Card employee education tool, a Best-Practices Utilization Model for onboarding and steerage, and the Regenexx Physician Network — a nationwide footprint of 60+ board-certified interventional orthopedics physicians trained through the Interventional Orthopedics Foundation.

Regenexx operates a transactional, savings-share revenue model: rather than charging per procedure, the company captures a percentage of the orthopedic surgical spend it helps the employer avoid, functioning as a cost-plus arrangement tied directly to documented MSK savings. Distribution runs through a direct field sales team targeting self-funded employers, supplemented by channel partnerships with major brokerages (Hylant, Hub International, Gilsbar, Relph Benefit Advisors) and implementation support from consulting partner ACAP Health. Customer-reported outcomes cite 50–70% MSK spend reduction, 90%+ surgery-avoidance rates, and over $100 million in cumulative client healthcare savings across 2,000+ employer clients.

Name

Regenexx Corporate

Legal name

Regenerative Sciences

Website

https://regenexxcorporate.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

251–500 employees

Short description

Regenexx Corporate sells non-surgical interventional orthopedic procedures (bone marrow concentrate and platelet-based injections) as a covered benefit to self-funded employers, brokers, and TPAs, capturing a share of the orthopedic surgical spend it helps clients avoid.

Ownership category

akta.pro rank

Product category

Interventional Orthopedics Services

NAICS

Offices of Physicians (62111)

SIC

Services-Health Services (8000), Services-Offices & Clinics Of Doctors Of Medicine (8011)

akta.pro primary industry

Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH)

Keywords

• Interventional orthopedics
• Orthobiologic procedures
• Self-funded employer benefits
• Bone marrow concentrate treatment
• MSK cost reduction

Headquarters

HQ city

Des Moines

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Orthopedic Benefit Cost Reduction: Regenexx generates revenue as a covered health benefit under employer self-funded health plans. The company charges based on a percentage reduction in orthopedic surgical spending for self-funded employers, functioning as a cost-plus or savings-sharing model rather than a per-procedure fee.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Regenexx Corporate offers non-surgical interventional orthopedic procedures—primarily bone marrow concentrate and platelet-based treatments delivered via precisely guided, needle-based injections—as a covered health benefit for self-funded employers. The company operates a network of 50+ clinics staffed by 60+ certified physicians and charges employers based on a percentage of orthopedic cost reduction, functioning as a savings-sharing rather than per-procedure fee model.

Product overview

Regenexx Corporate offers a unified employer benefit program built around its core Regenexx Procedures — patented, FDA-compliant bone marrow concentrate and platelet-based treatments that serve as non-surgical alternatives to orthopedic surgery. The portfolio centers on the Regenexx Corporate Program, which employers add to self-funded health plans to reduce orthopedic spend by up to 80%. Supporting the core procedures are several modules: the Regenexx Benefits Card (employee education tool), the Savings Calculator (employer ROI estimation), the Live Patient Outcomes Database (transparency/credibility), and the Best-Practices Utilization Model (onboarding and steerage framework). The company also operates a nationwide Regenexx Physician Network of 60+ certified clinics delivering standardized procedures, supported by an internal R&D division conducting clinical research and machine learning-based outcome prediction. Together, these components form a vertically integrated platform: employer-facing program delivery, network clinic operations, patient outcome tracking, and ongoing research development.

Differentiator

Problem solved

Functional benefit

Products and services

• Regenexx Corporate Program A self-funded employer benefit program that provides non-surgical interventional orthopedic procedures as an alternative to traditional orthopedic surgery, helping employers reduce healthcare costs by up to 80%.
• Regenexx Procedures Patented, FDA-compliant bone marrow concentrate and platelet-based procedures that treat orthopedic conditions through minimally invasive, needle-based injections guided by imaging technology.
• Regenexx Physician Network A nationwide network of over 60 board-certified physicians specializing in interventional orthopedics, trained and certified through the Interventional Orthopedics Foundation, providing standardized procedures across clinic locations.
• Regenexx Best-Practices Utilization Model A comprehensive onboarding and implementation framework including education tools, incentive programs, step therapy practices, and steerage strategies to maximize employee utilization and cost savings.

Quantifiable outcome

• Reduces MSK spending by 50-70%
• +4 more outcomes

Named customers6 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Six partnerships are on record, tiered core and minor.

• Hub InternationalcoreChannel Partner/ Reseller/ DistributorPartnership with Hub International, a leading insurance brokerage, to reduce orthopedic surgery costs for their self-funded employer clients through the Regenexx orthopedic benefit program.
• GilsbarcoreChannel Partner/ Reseller/ DistributorPartnership with Gilsbar to provide Regenexx orthopedic procedures as a cost-reduction benefit for self-funded employer health plans.
• HylantcoreChannel Partner/ Reseller/ DistributorHylant, an insurance brokerage firm, has partnered with Regenexx to offer their employer clients access to non-surgical orthopedic procedures as a covered health benefit.
• ACAP HealthcoreImplementation/ SI/ Consulting PartnerACAP Health serves as a consulting partner, featuring CEO interviews and helping facilitate implementation of the Regenexx orthopedic benefit program with employers.
• Relph Benefit Advisors (The Alera Group)minorChannel Partner/ Reseller/ DistributorBenefits advisor relationship with Relph Benefit Advisors, part of The Alera Group, featured in interviews discussing the Regenexx program.
• Pulse Health SolutionsminorChannel Partner/ Reseller/ DistributorBenefits advisor relationship with Pulse Health Solutions, featured in interviews discussing the Regenexx program for employer health benefits.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Organogenesis: Organogenesis is an established regenerative medicine company selling wound and soft-tissue biologic products into surgical and outpatient channels, providing a relevant broader incumbent comparable in regenerative biologics.
• Stryker: Stryker's orthopedic and surgical equipment divisions serve the same hospitals, ambulatory surgery centers, and surgeons that anchor the conventional orthopedic pathway Regenexx's employer benefit is designed to bypass.
• Zimmer Biomet: Zimmer Biomet is a global orthopedic medical device leader whose joint reconstruction and sports medicine franchises define the surgical standard Regenexx positions against as a non-surgical alternative.
• Vericel: Vericel is a commercial-stage regenerative medicine company selling cell therapy products (MACI, Epicel) into orthopedic and sports medicine indications, making it a comparable but broader regenerative medicine incumbent rather than a direct employer-benefit competitor.

Direct peers

• InGeneron: InGeneron develops autologous regenerative cell therapies for orthopedic and other musculoskeletal indications, overlapping directly with Regenexx's bone marrow concentrate and platelet-based orthobiologics technology.
• Kaia Health: Kaia Health provides digital MSK and chronic pain management programs marketed to employers and payers, competing for the same self-funded employer benefit dollar with a software-delivered alternative to in-person orthopedic care.
• Hinge Health: Hinge Health sells a digital MSK care program to self-funded employers as a covered benefit, competing head-on with Regenexx for HR and broker mindshare in the orthopedic benefit category, though its modality is virtual exercise therapy rather than in-clinic orthobiologics.
• Sword Health: Sword Health offers virtual MSK and pelvic health programs sold through employer benefits and health plans, going after the same self-funded employer buyers as Regenexx with a digital-first delivery model.

Emerging players

• Mesoblast: Mesoblast develops cellular medicines for inflammatory and musculoskeletal conditions, an emerging regenerative medicine player whose orthopedic pipeline overlaps conceptually with Regenexx's bone marrow concentrate approach.
• Personalized Stem Cells: Personalized Stem Cells is an early-stage company developing autologous stem cell therapies for orthopedic indications, making it an emerging direct competitor in the regenerative orthopedics space where Regenexx already operates.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/user/Regenexx
• Facebookfacebook.com/RegenexxCorporate
• LinkedInlinkedin.com/company/regenexx
• Xx.com/Regenexx

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Regenexx Corporate